Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87050 trials found · Page 95 of 4353
-
New weapon tested in fight against Tough-to-Treat blood cancer
Disease control OngoingThis open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belanta…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
Two-Drug attack on tough leukemia shows promise
Disease control OngoingThe purpose of this study is to test whether blinatumomab in combination with TKI therapy (such as dasatinib) is an effective treatment for people with Ph+ ALL. Researchers want to improve the response to standard-of-care treatment of corticosteroids + TKI therapy by adding the s…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New drug combo aims to keep deadly blood cancer at bay
Disease control CompletedThis study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA). Part 3 will be the Dose Finding portion to determine RPTD of venetoclax in combination with AZ…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Paramedics race against time to stop deadly sepsis before hospital
Disease control OngoingSepsis occurs when a serious infection - most commonly infection of the lungs, urinary system, or blood - leads to acute organ failure. It is a common, expensive, and frequently lethal condition. A growing body of evidence suggests that early recognition and treatment of sepsis c…
Phase: PHASE4 • Sponsor: Dr. Damon Scales • Aim: Disease control
Last updated Apr 14, 2026 13:10 UTC
-
New cell therapy offers hope for kids with rare leukemia
Disease control Recruiting nowThis is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CN…
Phase: PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC
-
Double-Punch immunotherapy trial aims to extend lives in advanced lung cancer
Disease control CompletedThe purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with …
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Could removing tubes first, ovaries later prevent ovarian cancer?
Prevention Recruiting nowThe aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
Phase: NA • Sponsor: University Medical Center Nijmegen • Aim: Prevention
Last updated Apr 24, 2026 16:19 UTC
-
Major trial hunts for drugs to put the brakes on devastating ALS
Disease control Recruiting nowMND-SMART is investigating whether selected drugs can slow down the progression of motor neuron disease (MND) and improve survival. The study is 'multi-arm' meaning more than one treatment will be tested at the same time. The trial started with 3 arms; drug 1 (memantine), drug 2…
Phase: PHASE2, PHASE3 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Experimental immune cell therapy tested for aggressive brain cancer
Disease control OngoingThis phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive)…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
Double attack: stem cell transplant plus CAR-T shows promise for tough lymphoma
Disease control CompletedThe goal of this clinical trial is to learn if sequential CD19/CD22 CAR-T cell therapy following autologous stem cell transplantation (ASCT) works to treat relapsed or refractory large B-cell lymphoma (LBCL) in adults. It will also learn about the safety of this treatment combina…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC
-
New targeted therapy shows promise for rare lung cancer subtype
Disease control OngoingThe reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of t…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
New transplant approach offers hope for rare immune and bone marrow diseases
Disease control Recruiting nowPhase II prospective trial to assess the rates of donor engraftment using reduced intensity conditioning (RIC) hematopoietic stem cell transplant (HSCT) and post-transplant cyclophosphamide (PTCy) for patients with primary immune deficiencies (PID), immune dysregulatory syndromes…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC
-
New hope for advanced thyroid cancer patients in major drug trial
Disease control OngoingThe reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other…
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
Scientists test gene therapy to restore vision in blinding eye disease
Disease control Recruiting nowA Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Phase: PHASE1, PHASE2 • Sponsor: Bionic Sight LLC • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
Major trial tests new weapon against aggressive lung cancer
Disease control CompletedThis study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be stratif…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Stem cell patch could be lifeline for failing hearts
Disease control Recruiting nowThe BioVAT-HF trial will test the hypothesis that cardiomyocyte implantation via engineered heart muscle (EHM), the proposed investigational medicinal product (IMP; designated "Biological Ventricular Assist Tissue" or BioVAT), results in sustainable remuscularization and biologic…
Phase: PHASE1, PHASE2 • Sponsor: University Medical Center Goettingen • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
New Triple-Drug combo shows promise against aggressive breast cancer
Disease control OngoingThis study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in participants with PIK3CA-mutant, hormone receptor (HR)-positive, HER2-negative locally advan…
Phase: PHASE2, PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
Gene therapy for fatal brain disease: Long-Term safety check
Disease control OngoingThis is a long-term safety and efficacy study in subjects with CLN6 Batten disease who previously received a single intrathecal administration of AT-GTX-501.
Sponsor: Emily de los Reyes • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
Brain pacemaker tested to reset depression circuits
Disease control OngoingOf the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depr…
Phase: NA • Sponsor: Helen Mayberg, MD • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
Radiation boost could let rectal cancer patients skip major surgery
Disease control Recruiting nowIn recent years, an increasing number of retrospective and prospective observational studies have indicated that a subset of rectal cancer patients may avoid surgery if they can achieve a complete response to chemoradiotherapy. Prospective trials, including the previous Danish Wa…
Phase: PHASE3 • Sponsor: Vejle Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC